SCHEMBL120256

SCHEMBL120256

COC(=O)c1ccc(S(=O)(=O)Nc2ncc(C)cc2Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
CYP2C9 P11712 5/20 0.51
FLT1 P17948 1/20 0.48
FLT4 P35916 1/20 0.48
KDR P35968 1/20 0.48
TCF4 P15884 1/20 0.48
CTNNB1 P35222 1/20 0.48
ALDH1A1 P00352 6/20 0.46
TSHR P16473 4/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MAPT P10636 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GAA P10253 1/20 0.46
ALOX15 P16050 1/20 0.46
HTT P42858 1/20 0.46
CYP1A2 P05177 1/20 0.46
POLB P06746 1/20 0.46
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL121322 0.89 CCR4 (0.47) MEN1KMT2ATDP1CYP2C9FLT1
SCHEMBL118688 0.89 FLT1 (0.55) MEN1KMT2ATDP1CYP2C9FLT1
SCHEMBL119695 0.84 MEN1 (0.71) MEN1KMT2ATDP1ALDH1A1NPSR1
SCHEMBL119346 0.83 CYP2C9 (0.51) MEN1KMT2ATDP1CYP2C9FLT1
SCHEMBL118204 0.80 TSHR (0.53) KMT2ACYP2C9FLT1FLT4KDR
SCHEMBL3160292 0.75 SCN3A (0.52) KMT2ACYP2C9FLT1FLT4KDR
SCHEMBL16119560 0.73 CYP2C9 (0.76) KMT2ACYP2C9FLT1FLT4KDR
SCHEMBL29535237 0.73 CYP2C9 (0.76) KMT2ACYP2C9FLT1FLT4KDR
SCHEMBL119812 0.73 SLC7A11 (0.54) KMT2ACYP2C9TCF4CTNNB1ALDH1A1
SCHEMBL118604 0.73 MEN1 (0.54) MEN1KMT2ATDP1CYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102427810-A Sulfamoylbenzoic acid derivatives as TRPM8 antagonists RAQUALIA PHARMA INC 2012-04-25 CN disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
EP-2424517-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RaQualia Pharma Inc (JP) 2012-03-07 EP disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 MEN1 1593/4885KMT2A 941/4885TDP1 4578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.